Anticoagulation Management Post Pulmonary Embolism.
Joseph J NaoumPublished in: Methodist DeBakey cardiovascular journal (2024)
Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.
Keyphrases
- end stage renal disease
- chronic kidney disease
- venous thromboembolism
- peritoneal dialysis
- pulmonary embolism
- atrial fibrillation
- direct oral anticoagulants
- obese patients
- newly diagnosed
- ejection fraction
- preterm infants
- patient reported outcomes
- inferior vena cava
- systematic review
- randomized controlled trial
- growth factor
- patient reported
- genetic diversity